Camrelizumab

Elevar Therapeutics To Present Two Posters From Phase 3 CARES-310 Study at 2024 ASCO Gastrointestinal Cancers Symposium

Retrieved on: 
Thursday, January 18, 2024

ASCO GI will be held Jan. 18-20, 2024, at the Moscone Convention Center (West) in San Francisco, and online.

Key Points: 
  • ASCO GI will be held Jan. 18-20, 2024, at the Moscone Convention Center (West) in San Francisco, and online.
  • Elevar’s poster presentations are:
    Abstract Title: Impact of baseline liver function on survival outcomes in patients with unresectable hepatocellular carcinoma (uHCC) treated with camrelizumab + rivoceranib vs sorafenib: A post hoc analysis of study CARES-310.
  • The results of this post-hoc analysis may have implications for selection of initial and subsequent therapies for uHCC patients.
  • The FDA assigned Prescription Drug User Fee Act (PDUFA) target action dates in May 2024.

Elevar Therapeutics Joins Benefactors Council of Blue Faery, Leading Hepatocellular Carcinoma Advocacy Group

Retrieved on: 
Tuesday, September 19, 2023

Blue Faery’s Benefactors Council comprises corporations and/or individuals committed to giving an annual gift for HCC research, educational programs, patient advocacy events and/or corporate sponsorships.

Key Points: 
  • Blue Faery’s Benefactors Council comprises corporations and/or individuals committed to giving an annual gift for HCC research, educational programs, patient advocacy events and/or corporate sponsorships.
  • “Elevar is inspired by Blue Faery’s efforts to raise understanding of and advocate for patients with hepatocellular carcinoma and their families,” said Elevar Vice President of Medical Affairs Bill Strickland.
  • “As Elevar Therapeutics enters the final stages of clinical development for its promising HCC therapy, Blue Faery is delighted to welcome the company to our Benefactors Council,” said Andrea Wilson Woods, president, founder and founding director of Blue Faery.
  • “Elevar recognizes that success in taking on HCC means working together to advocate for those in need.

Elevar Therapeutics Announces Publication of Phase 3 CARES 310 Study Results in The Lancet

Retrieved on: 
Tuesday, July 25, 2023

FORT LEE, N.J., July 24, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced the publication of its Phase 3 CARES 310 study results in The Lancet.

Key Points: 
  • FORT LEE, N.J., July 24, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options, today announced the publication of its Phase 3 CARES 310 study results in The Lancet.
  • The study assessed the combination of Elevar’s drug candidate rivoceranib, an oral TKI, in combination with camrelizumab, a PD-1 inhibitor, as a first-line therapy for unresectable hepatocellular carcinoma (uHCC).
  • “As evidenced in the CARES 310 study, camrelizumab plus rivoceranib demonstrate significant promise as a potentially improved therapy for advanced hepatocellular carcinoma,” said Saeho Chong, Elevar chief executive officer.
  • With efficacy results generally consistent across all subgroups, the CARES 310 data suggested the combination confers a benefit in a global uHCC population.

HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting

Retrieved on: 
Thursday, May 25, 2023

13 presentations and publications, including several investigator-initiated-trials (“IITs”), are listed in the table below.

Key Points: 
  • 13 presentations and publications, including several investigator-initiated-trials (“IITs”), are listed in the table below.
  • These new analyses add to the understanding of fruquintinib efficacy by specific lines of therapy as well as adverse events of special interest (“AESI”).
  • Median PFS was not reached when results from this study were initially presented at the 2021 Chinese Society of Clinical Oncology Annual Meeting (data cut-off on August 31, 2021).
  • Preclinical data presented at the American Association for Cancer Research Annual Meeting 2023 (AACR 2023) showed that it has strong activity against FGFR-deregulated tumors, supporting investigation in patients with FGFR alterations (such as fusion and mutation) either as a single agent or in combination with PD-1 blockade.

Hepatocellular Carcinoma Treatment Market Forecasts, Epidemiology & Pipeline Analysis Report 2022-2027 - ResearchAndMarkets.com

Retrieved on: 
Tuesday, January 24, 2023

The "Hepatocellular Carcinoma Treatment Market Forecast- Epidemiology & Pipeline Analysis 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Hepatocellular Carcinoma Treatment Market Forecast- Epidemiology & Pipeline Analysis 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • Many new classes of therapies are looking to enter the global hepatocellular carcinoma treatment market over the next few years.
  • Among 8MM, the US accounts for a significant market share of 48.07%, with a CAGR of 19.33% in the hepatocellular carcinoma treatment market.
  • The global hepatocellular carcinoma treatment market is dominated by many companies offering generic drugs and selective pharma/biotech companies offering patented/commercial drugs for treating hepatocellular carcinoma.

Elevar Therapeutics Announces Data From Phase 3 Study of Rivoceranib in Combination With Camrelizumab Is Accepted for Late-Breaking Proffered Paper Presentation at ESMO Congress 2022

Retrieved on: 
Thursday, August 25, 2022

Rivoceranib is a highly potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), a primary pathway for tumor angiogenesis.

Key Points: 
  • Rivoceranib is a highly potent inhibitor of vascular endothelial growth factor receptor 2 (VEGFR-2), a primary pathway for tumor angiogenesis.
  • Rivoceranib is co-developed by Jiangsu Hengrui Pharmaceuticals Co., Ltd. (JHP) in China and by Elevar Therapeutics, Inc. globally (excluding China).
  • Rivoceranib is currently being studied as a monotherapy and in combination with chemotherapy and immunotherapy in various solid tumor indications.
  • Elevar holds the global rights (excluding China) and has partnered for the development and marketing of rivoceranib with HLB-LS in South Korea.

Elevar Therapeutics Receives Orphan Drug Designation from FDA for Rivoceranib for the Treatment of Hepatocellular Carcinoma (HCC)

Retrieved on: 
Thursday, November 11, 2021

SALT LAKE CITY, Nov. 11, 2021 /PRNewswire/ --Elevar Therapeutics, Inc. ("Elevar"), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options,today announced that the U.S. Food and Drug Administration (FDA) has granted rivoceranib with orphan drug designation for the treatment of hepatocellular carcinoma (HCC).

Key Points: 
  • SALT LAKE CITY, Nov. 11, 2021 /PRNewswire/ --Elevar Therapeutics, Inc. ("Elevar"), a fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options,today announced that the U.S. Food and Drug Administration (FDA) has granted rivoceranib with orphan drug designation for the treatment of hepatocellular carcinoma (HCC).
  • "The orphan drug designation granted by the FDA recognizes the potential of rivoceranib to address the urgent unmet need for new therapies that can improve patient outcomes for people with HCC," said Kate McKinley, Chief Executive Officer of Elevar Therapeutics.
  • Orphan Drug designations have been granted in gastric cancer (U.S., EU, and South Korea), adenoid cystic carcinoma (U.S.) and hepatocellular carcinoma (U.S.).
  • Elevar Therapeutics holds the global rights (excluding China) and has partnered for the development and marketing of rivoceranib with HLB-LS in South Korea.

LSK BioPharma and Jiangsu Hengrui Medicine Announce Global Clinical Collaboration to Evaluate the Combination of Anti-Angiogenesis and Immuno-Oncology Therapy for Patients with Advanced Hepatocellular Carcinoma (HCC)

Retrieved on: 
Monday, October 22, 2018

LSKB will retain full commercial rights for rivoceranib outside of China and Hengrui will retain full commercial rights for camrelizumab worldwide.

Key Points: 
  • LSKB will retain full commercial rights for rivoceranib outside of China and Hengrui will retain full commercial rights for camrelizumab worldwide.
  • Sung Chul Kim, LSKB's President, "we are enthusiastic to work with Hengrui for the potential to help more patients by combining rivoceranib with camrelizumab."
  • "We look forward to partnering with LSKB to build upon the existing preclinical and clinical data and further explore this combination therapy for patients with hepatocellular carcinoma, an area of high unmet medical needs."
  • Through years of effort, Hengrui has built a robust oncology pipeline, which holds significant potential to benefit cancer patients.